Capricor Therapeutics Inc.

06/28/2024 | Press release | Distributed by Public on 06/28/2024 07:03

Capricor Therapeutics Announces Long Term Benefit of Deramiocel (CAP 1002) in Both Skeletal Muscle and Cardiac Function in the HOPE 2 OLE Study in Duchenne Muscular Dystrophy